Chemotherapy-induced peripheral neuropathy research: a National Institutes of Health (NIH) grant portfolio analysis (2014-2023)
The number of CIPN grants awarded by NIH since 2014 represents a substantial investment, but critical gaps and opportunities remain. Preclinically, novel strategies to mimic human CIPN may improve translatability. Important gaps in CIPN-associated cancer diagnoses and therapy exposures, including novel agents, would benefit from future research. Also, clinical studies are needed in young patients with potential long-term CIPN.
Authors
- Catherine A. Schweppe
- Nina S. Kadan‐Lottick (ORCID: https://orcid.org/0000-0002-6857-396X)
- Rachel D. Altshuler (ORCID: https://orcid.org/0000-0002-1771-9287)
- Lori M. Minasian
Institutions
- National Institutes of Health (US)
- Georgetown University (US)
- Georgetown University Medical Center (US)
- National Cancer Institute (MY)
- National Cancer Institute (US)
- Georgetown Lombardi Comprehensive Cancer Center
Publication Details
- Journal
- JNCI Cancer Spectrum
- Published
- 2025-04-21
- DOI
- https://doi.org/10.1093/jncics/pkaf039
- Citations
- 3
- Primary Topic
- Cancer Treatment and Pharmacology
- Type
- article
- Field-Weighted Citation Impact
- 3.14
Funders
- Australian Government
- National Cancer Institute